Design Therapeutics (DSGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.32
- Estimate
- -$0.34
- Surprise
- +7.1%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Design Therapeutics (DSGN) reported a narrower loss than forecast — diluted EPS of -$0.32 against the -$0.34 estimate (a 7.1% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates DSGN Sell at 5.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +7.1% surprise compares with a +14.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: GeneTAC platform technologies
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.99
- Price target
- $18.27
- Stop
- $13.94
- Upside to target
- +21.9%
- Reward-to-risk
- 1.5:1
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
DSGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $938.1M
- P/E (fwd)
- -9.4
- 52-week range
- $4.92–$17.25
- Off 52-week high
- 13.1%
- RSI (14)
- 74
- Volume vs avg
- 1.13×
- Score today
- 5.5/10